| Business Summary | | Viragen
(Europe)
Ltd.,
an
89%
owned
subsidiary
of
Viragen,
Inc.,
is
in
the
business
of
researching,
developing
and
manufacturing
products
that
help
the
human
immune
system
resist
viral
infections,
and
related
technologies.
The
Company,
through
a
license
granted
by
its
parent
company
Viragen,
Inc.,
has
certain
exclusive
rights
in
the
European
Union
and
certain
non-exclusive
rights
throughout
the
rest
of
the
world,
excluding
the
United
States
and
its
territories,
to
engage
in
the
manufacture
and
distribution
of
certain
immunological
products,
particularly
human
leukocyte
derived
interferon.
The
license
encompasses
Viragen,
Inc.'s
Omniferon
product,
a
natural
interferon
product.
Natural
interferon
stimulates
and
controls
the
human
immune
system.
In
addition,
interferon
may
stem
the
growth
of
various
viruses
including
those
involved
with
diseases
like
hepatitis,
cancer,
multiple
sclerosis,
and
HIV/AIDS. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Viragen,
and
its
subsidiaries,
are
involved
in
the
research,
development
and
manufacture
of
certain
immunological
products
for
commercial
application.
For
the
nine
months
ended
3/31/01,
revenues
rose
from
$459
to
$146
thousand.
Net
loss
rose
10%
to
$5.4
million.
Revenues
reflect
export
sales
of
OMNIFERON.
Higher
loss
reflects
increased
general
and
administrative
expenses
and
higher
R&D
costs
related
to
the
OMNIFERON
product
and
collaborative
agreements. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| Gerald Smith, 69 Chairman,
Pres, CEO | $82K | D. Magnus Nicolson, 40 COO,
Director and Managing Director of Viragen (Scotland) Ltd. | 170K | Dennis Healey, 52 Exec.
VP, Treasurer, Sec., Director | 57K | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|